These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36465958)

  • 21. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.
    VanderZwaag B; Garcia-Romeu A; Garcia-Barrera MA
    Ther Adv Psychopharmacol; 2024; 14():20451253241264812. PubMed ID: 39132012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.
    Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR
    J Psychoactive Drugs; 2024; 56(4):456-466. PubMed ID: 37449499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.
    Nadeem Z; Parker S; McGovern H; Oestreich LK
    Aust N Z J Psychiatry; 2024 Oct; 58(10):904-913. PubMed ID: 38907608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
    Vina SM
    J Racial Ethn Health Disparities; 2024 May; ():. PubMed ID: 38753105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
    Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
    Front Psychiatry; 2021; 12():687546. PubMed ID: 34220590
    [No Abstract]   [Full Text] [Related]  

  • 36. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index (BMI) does not predict responses to psilocybin.
    Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2023 Jan; 37(1):107-116. PubMed ID: 36373934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.
    Simonsson O; Osika W; Stenfors CUD; Goldberg SB; Honk L; Hendricks PS
    Psychol Med; 2024 Apr; 54(6):1228-1234. PubMed ID: 37859627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
    Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L
    Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.